NASDAQ:UBXUnity Biotechnology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Unity Biotechnology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.96 +0.60 (+7.18 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$8.36Now: $8.96▼$8.9650-Day Range$6.51MA: $8.26▼$9.6752-Week Range$4.62Now: $8.96▼$10.38Volume302,969 shsAverage Volume460,219 shsMarket Capitalization$440.29 millionP/E RatioN/ADividend YieldN/ABeta0.37 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, Unity Biotechnology has a potential upside of 145.5% from its current price of $8.96.Amount of Analyst CoverageUnity Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesUnity Biotechnology has received 125 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUnity Biotechnology has received 122 “underperform” votes. (Add your “underperform” vote.)Community SentimentUnity Biotechnology has received 50.61% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote “Outperform” if you believe UBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUnity Biotechnology does not currently pay a dividend.Dividend GrowthUnity Biotechnology does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unity Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders37.30% of the stock of Unity Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.56% of the stock of Unity Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Unity Biotechnology are expected to grow in the coming year, from ($1.92) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unity Biotechnology is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unity Biotechnology is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UBX Previous Symbol CUSIPN/A CIK1463361 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees94 Outstanding Shares49,140,000Market Cap$440.29 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:UBX Rates by TradingView Receive UBX News and Ratings via Email Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter. Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)? Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UBX stock has increased by 66.2% and is now trading at $8.96. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Unity Biotechnology? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Unity Biotechnology. When is Unity Biotechnology's next earnings date? Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Unity Biotechnology. How were Unity Biotechnology's earnings last quarter? Unity Biotechnology Inc (NASDAQ:UBX) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.03. View Unity Biotechnology's earnings history. What price target have analysts set for UBX? 3 analysts have issued twelve-month price targets for Unity Biotechnology's stock. Their forecasts range from $13.00 to $33.00. On average, they expect Unity Biotechnology's stock price to reach $22.00 in the next year. This suggests a possible upside of 145.5% from the stock's current price. View analysts' price targets for Unity Biotechnology. Has Unity Biotechnology been receiving favorable news coverage? News articles about UBX stock have trended negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Unity Biotechnology earned a news impact score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Unity Biotechnology. Are investors shorting Unity Biotechnology? Unity Biotechnology saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,670,000 shares, an increase of 8.1% from the June 15th total of 4,320,000 shares. Based on an average daily volume of 288,500 shares, the short-interest ratio is currently 16.2 days. Approximately 18.6% of the company's stock are short sold. View Unity Biotechnology's Current Options Chain. Who are some of Unity Biotechnology's key competitors? Some companies that are related to Unity Biotechnology include Aurinia Pharmaceuticals (AUPH), CENTRIC HEALTH (CHH), SpringWorks Therapeutics (SWTX), USANA Health Sciences (USNA), Madrigal Pharmaceuticals (MDGL), Passage Bio (ZNTL), Glaukos (GKOS), Akebia Therapeutics (AKBA), Editas Medicine (EDIT), INDIVIOR PLC/S (INVVY), I-Mab (IMAB), Adverum Biotechnologies (ADVM), Y-mAbs Therapeutics (YMAB), Polynovo (PNV) and Zymeworks (ZYME). View all competitors. What other stocks do shareholders of Unity Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), NIO (NIO), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.Com (JD), Sorrento Therapeutics (SRNE) and Advanced Micro Devices (AMD). Who are Unity Biotechnology's key executives? Unity Biotechnology's management team includes the following people: Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)Dr. Anirvan Ghosh, Director & CEO (Age 56)Dr. Jan M. van Deursen, FounderDr. Judith Campisi, Founder When did Unity Biotechnology IPO? (UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. What is Unity Biotechnology's stock symbol? Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX." How do I buy shares of Unity Biotechnology? Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Unity Biotechnology's stock price today? One share of UBX stock can currently be purchased for approximately $8.96. How big of a company is Unity Biotechnology? Unity Biotechnology has a market capitalization of $440.29 million. Unity Biotechnology employs 94 workers across the globe. This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
